However, in tumours with reduced sensitivity to KRASG12C inhibition, such as the KPAR.M7 model we generated, we observed that despite being sensitised to anti-PD-1 blockade with RASG12C(ON) inhibition, addition of SHP2 inhibitor can enhance further anti-tumour immunity and result in tumour eradication. Here, PDCD1 is linked to neoplasm.